Changes of CD3+,CD3+CD4+ and CD3+CD8+T lymphocytes before and after treatment in patients with leukemia and their significance

doi:10.3969/j.issn.1673-8640.2016.05.010

Abstract

Abstract:

Objective To investigate the changes of T lymphocyte subsets （CD3⁺,CD3⁺CD4⁺,CD3⁺CD8⁺T cells） in peripheral blood before and after treatment in patients with leukemia and their significance. Methods SemiBio Slide assay was used to determine 100 leukemia patients [45 cases of acute lymphoblastic leukemia（ALL） and 55 cases of non-acute lymphoblastic leukemia （N-ALL）] and 90 healthy subjects（healthy control group） for peripheral blood T lymphocyte subsets as absolute value. Simultaneously,IgG,IgA and IgM were determined. According to remission after treatment,the patients with leukemia were classified into remission group（48 cases,21 cases of ALL and 27 cases of N-ALL） and non-remission group（52 cases,24 cases of ALL and 28 cases of N-ALL）. Results In ALL group and N-ALL group,peripheral blood CD3⁺and CD3⁺CD4⁺T cell absolute values,CD3⁺CD4⁺/CD3⁺CD8⁺ratio,IgG,IgA and IgM levels were significantly lower than those in healthy control group（P<0.05）. CD3⁺CD8⁺T cell absolute values were slightly higher than those in healthy control group,but there was no statistical significance（P>0.05）. Whether it is ALL or N-ALL,after treatment, CD3⁺and CD3⁺CD4⁺T cell absolute values,CD3⁺CD4⁺/CD3⁺CD8⁺ratio,IgG,IgA and IgM in remission group was significantly higher than those before treatment （P<0.05）,which were close to those in healthy control group （P>0.05）. There was no statistical significance in non-remission group between before and after treatment（P>0.05）. Conclusions The determination of T lymphocyte subsets （CD3⁺,CD3⁺CD4⁺,CD3⁺CD8⁺T cells） using absolute values has certain significance for disease monitoring and prognosis in leukemia patients.

Key words: T lymphocyte subsets, Absolute values, Leukemia, Immune function

CLC Number:

R446.63

YUAN Yongming, CHENG Li, ZHANG Shu, PENG Xianchong, QU Bin. Changes of CD3⁺,CD3⁺CD4⁺ and CD3⁺CD8⁺T lymphocytes before and after treatment in patients with leukemia and their significance[J]. Laboratory Medicine, 2016, 31(5): 387-391.

Figures/Tables 3

References 12

[1]	李扬秋,陈少华,查显丰.髓性白血病的免疫调节和细胞免疫治疗研究进展[J].暨南大学学报(自然科学与医学版),2013,78(6):571-576.
[2]	吴巨峰,李扬秋,姚红霞,等.急性白血病患者化疗前后外周血T细胞亚群检测的临床意义[J].海南医学,2011,22(1):4-6.
[3]	吕卫东,张平安.特异性免疫玻片法在外周血T淋巴细胞亚群检测中的应用[J]. 微循环学杂志,2011,21(1):51-52.
[4]	KEPPLE J,HENRY-TILLMAN RS,KLIMBERG VS,et al.The receptor expression pattern in ductal carcinoma in situ predicts recurrence[J]. Am J Surg,2006,192(1):68-71.
[5]	张婧瑶,许洪志,尹冬梅,等.再生障碍性贫血、骨髓增生异常综合征、急性髓系白血病患者CD8+T细胞亚群的变化及临床意义[J].中国实验血液学杂志,2013,21(1):203-208.
[6]	江虹,李菊湘. T淋巴细胞亚群在恶性肿瘤患者外周血中的变化[J].检验医学与临床,2010,7(13):1361-1362.
[7]	李辉,吴雨洁,仇海荣,等.T淋巴细胞亚群结合遗传学检测在初发急性白血病中的相关研究[J].现代检验医学杂志,2010,25(2):84-86.
[8]	朱孟霞,许莲蓉,张耀方.急性髓性白血病患者外周血淋巴细胞亚群的检测及其临床意义[J].中国医药指南,2013,11(21):32-33.
[9]	孔令君,葛健,夏瑞祥. Treg 和淋巴细胞亚群在急性髓系白血病中的意义[J]. 安徽医科大学学报,2015,61(4):512-514.
[10]	徐卫,李建勇,姚建新,等.慢性淋巴细胞性白血病外周血T细胞亚群及免疫球蛋白研究[J].白血病·淋巴瘤,2007,16(5):365-367.
[11]	梁虹,姚福生,赵海军,等.血液肿瘤患者化疗前后T淋巴细胞亚群检测分析[J].安徽医药,2011,15(11):1391-1393.
[12]	庄万传,李秀梅,韩秀华.恶性血液病患者化疗前后淋巴细胞亚群测定及其意义[J]. 白血病·淋巴瘤,2006,15(6):442-443.

组别	例数	CD3⁺T细胞（个/µL）	CD3⁺CD4⁺T细胞（个/µL）	CD3⁺CD8⁺T细胞（个/µL）	CD3⁺CD4⁺/CD3⁺CD8⁺比值
ALL组	45	1 086±372^*	676±252^*	584±212	1.12±0.39^*
N-ALL组	55	1 141±374^*	718±273^*	599±216	1.20±0.45^*
正常对照组	90	1 436±404	884±232	545±198	1.69±0.47

组别	例数	CD3⁺T细胞（个/µL）	CD3⁺CD4⁺T细胞（个/µL）	CD3⁺CD8⁺T细胞（个/µL）	CD3⁺CD4⁺/CD3⁺CD8⁺比值
ALL组	45	1 086±372^*	676±252^*	584±212	1.12±0.39^*
N-ALL组	55	1 141±374^*	718±273^*	599±216	1.20±0.45^*
正常对照组	90	1 436±404	884±232	545±198	1.69±0.47

组别	检测时间	例数	IgG	IgA	IgM
ALL组		45	9.82±1.56^*	1.52±0.56^**	0.96±0.32^*
缓解组	治疗前	21	9.68±1.43^*	1.68±0.62^**	0.95±0.31^*
	治疗后	21	12.12±1.98^#	2.47±0.87^#	1.41±0.48^#
未缓解组	治疗前	24	9.46±1.33^*	1.56±0.59^**	0.89±0.28^*
	治疗后	24	9.57±1.35^*	1.69±0.61^**	0.97±0.33^*
N-ALL组		55	10.54±1.87^*	1.89±0.64^*	1.01±0.34^*
缓解组	治疗前	27	9.98±1.57^*	1.74±0.65*	0.99±0.32^*
	治疗后	27	12.87±2.15^#	2.26±0.81^#	1.47±0.50^#
未缓解组	治疗前	28	9.54±1.32^*	1.82±0.69^*	0.89±0.27^*
	治疗后	28	9.77±1.39^*	1.90±0.71^*	0.87±0.26^*
正常对照组		90	12.30±2.00	2.35±0.82	1.35±0.47

组别	检测时间	例数	IgG	IgA	IgM
ALL组		45	9.82±1.56^*	1.52±0.56^**	0.96±0.32^*
缓解组	治疗前	21	9.68±1.43^*	1.68±0.62^**	0.95±0.31^*
	治疗后	21	12.12±1.98^#	2.47±0.87^#	1.41±0.48^#
未缓解组	治疗前	24	9.46±1.33^*	1.56±0.59^**	0.89±0.28^*
	治疗后	24	9.57±1.35^*	1.69±0.61^**	0.97±0.33^*
N-ALL组		55	10.54±1.87^*	1.89±0.64^*	1.01±0.34^*
缓解组	治疗前	27	9.98±1.57^*	1.74±0.65*	0.99±0.32^*
	治疗后	27	12.87±2.15^#	2.26±0.81^#	1.47±0.50^#
未缓解组	治疗前	28	9.54±1.32^*	1.82±0.69^*	0.89±0.27^*
	治疗后	28	9.77±1.39^*	1.90±0.71^*	0.87±0.26^*
正常对照组		90	12.30±2.00	2.35±0.82	1.35±0.47

组别	检测时间	例数	CD3⁺T细胞（个/µL）	CD3⁺CD4⁺T细胞（个/µL）	CD3⁺CD8⁺T细胞（个/µL）	CD3⁺CD4⁺/CD3⁺CD8⁺比值
ALL组
缓解组	治疗前	21	1 131±379	680±256	590±223	1.10±0.36
	治疗后	21	1 382±398^*	845±261^*	581±218	1.54±0.42^*
未缓解组	治疗前	24	1 095±360	679±248	584±208	1.09±0.38
	治疗后	24	1 147±375	668±231	598±221	1.19±0.43
N-ALL组
缓解组	治疗前	27	1 186±386	701±264	594±234	1.16±0.37
	治疗后	27	1 409±393^*	853±269^*	591±224	1.60±0.45^*
未缓解组	治疗前	28	1 175±379	698±258	601±241	1.17±0.32
	治疗后	28	1 195±387	702±265	614±248	1.20±0.41